Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Recovery is under way.
This will go on to make new highs.
This is a good time to get in.
ouch 12.77 -4,48 ( -25,97 %)
Micro float.
77 percent institutional ownership.
$200 million in cash to fuel growth.
Rapid growth and expansion.
Zero float.
Combined enterprise value: $900 million.
Stock worth $75 on fundamentals alone.
Why would have this 77 percent institutional ownership:
Now you know the answer.
This will pop to $50 again.
Just a matter of time.
This current price is a 600 percent discount.
Combined enterprise value is $900 million.
They are cash rich to fuel rapid growth.
77 percent institutional ownership.
Micro float.
Zero dilution.
This hit $50.50 a few days ago.
This can hit $75 at some point.
This dip is a golden opportunity to load some more.
Well I called my broker and according to him its not a "forced" tender....optional....hmmmmm.....any ideas out there? Is there anybody out there? lol Its nice to have options though!
So whats the deal here? Should we call our broker and accept the tender offer or not accept? Does anyone know if a actual class action suit has been filed? Any suggestions? I was hoping to ride this baby to $60 a share but obviously the powers that be knew it was a winner and bought us out at 15. Now maybe its a good deal and maybe its not...just interested in others opinions.
I am a complete nobody...do not buy or sell due to my poor excuse for a comment!
Tender offer > On September 28, 2014, Ambit Biosciences Corporation (“Ambit”) and Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) issued a joint press release announcing the execution of an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the Merger Agreement, Charge Acquisition Corp., a wholly-owned subsidiary of Daiichi Sankyo (“Purchaser”), will commence a tender offer (the “Offer”) to purchase all of the issued and outstanding shares of Ambit common stock for (a) $15.00 per share in cash, plus (b) one non-transferrable contingent value right for each share of Ambit common stock, which represents the contractual right to receive up to $4.50 per share upon the achievement of certain commercialization-related milestones. If successful, the Offer will be followed by a merger of Purchaser with and into Ambit (the “Merger”).
lol beginners luck. Had no idea we would move this fast. Nice!!
Looks like you were right!
Time to load up now before the run to 18-22 range imho! 8 is becoming a thing of the past...9 just the beginning of this!!!
All my opinion...risk to all stocks!
I told you at 6....then 7....now 8 dollars and climbing. We have a long way to go to 18 but we will be there before you know it. Don't say I didn't warn you!
All simply my humble opinion and anyone investing be prepared as always to lose everything.
I tried to tell you guys! Brace yourselves cause this baby is going to really take off now! Last chance to ride the big wave! Surfs up AMBI$$$$$$$$$$$$$$
loading....loading...loading.....$$$AMBI$$$....going to ride this wave a coming!
AMBI- Share Structure
Shares Outstanding5: 17.97M
Float: 5.07M
AMBI- Share Structure
Shares Outstanding5: 17.97M
Float: 5.07M
One seller is causing this to drop, don't be afraid to step in and buy, Mm's playing games to create more sellers.... Company assured me all is well and they are aware it's only one seller
Who know, we could close above $12 today!!!!!!
Company has no rev yet. That's why.
Any snags in the pipeline really jack with valuation here. I have small position in at near bottom from first huge sell off. Damn FDA like to have things their way.
Good luck to ya. I hope you're right and we see the teens sooner than later.
This should easily be @ $18, not sure what is holding it back bug it's coming soon, that amount doesn't even include the approval for any of the drugs
Awesome. That's good news. Thanks for the update!
So, I'm going by his word and will continue to load up
IR called me back, sounds like one seller unloading a position....some of the buyers are actually on their way back from the JP Morgan Conference so there is a trade imbalance possibly allowing for these crazy swings, he told me the company is very upbeat on the future!!!
I'm not sure at all, called investor relations, gonna shoot over an email right now, this has me way down and very concerned
I'm not sure at all, called investor relations, gonna shoot over an email right now, this has me way down and very concerned
Any news / gossip on what might be causing this?
Hope it worked out well for you, my friend! AMBI was a good find.
Getting ready to add 100,000 shares, perfect timing!!!!
Yes, Sir. I hope you caught the ride as well! This isn't rocket science IMHO. Solid prospects with a good track record and past performance. Drives all of my selections on here. AMBI
Hope your still in!!!!!
3:32AM Ambit Biosciences announces 4 presentations including results of phase 2b randomized, open-label study of lower doses of quizartinib in flt3 itd positive relapsed refractory acute myeloid leukemia patients (AMBI) 8.31 : Co announces four oral presentations given at the 55th Annual ASH Conference in New Orleans, with data highlighting the Company's lead drug candidate, quizartinib.
Results of the Phase 2b Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML): The purpose of this study is to assess the efficacy and safety of lower doses of quizartinib in the treatment of patients 18-years or older with relapsed/refractory FLT3 ITD positive AML to further improve the benefit:risk assessment of quizartinib.
This preliminary analysis is based on data available through May 28, 2013 with a minimum of eight weeks of follow up since the last subject first visit. A total of 76 patients were enrolled from May 21, 2012 to March 27, 2013. Median age for all patients was 55 (19-77) and 92% were FLT3-ITD. 35 patients remained in follow-up at the time of the analysis, and are currently censored for overall survival. The following key information was presented:
For dose of 30mg:
The CRc rate was 47 percent (5 percent CR+CRp, 42 percent CRi)
The rate of HSCT after quizartinib use was 32 percent
The median overall survival was 20.7 weeks, with 16/38 patients censored as they remained in follow-up at the time of the analysis
Of the 12 patients who were bridged to HSCT, the median overall survival was 31 weeks
Grade 2 or greater QT prolongation was 11%, with a 5% grade 3 rate and no grade 4 events
For dose of 60mg:
The CRc rate was 47 percent (5 percent CR+CRp, 42 percent CRi)
The rate of HSCT after quizartinib use was 42 percent
The median overall survival was 25.4 weeks, with 19/38 patients censored as they remained in follow-up at the time of the analysis
Of the 16 patients who were bridged to HSCT, the median overall survival is 28.1 weeks
Grade 2 or greater QT prolongation was 17%, with a 3% grade 3 rate and no grade 4 events
Overall conclusions: Both the 30mg and the 60mg doses showed substantial activity in terms of overall CRc rate and bridge to HSCT with impact on improved median OS. The safety profile is similar at both doses yet QTcF prolongation appears dose dependent, with decreased QTcF prolongation at both the 30 and 60mg doses compared to the prior Phase 2 study findings which utilized higher doses of quizartinib.
Next steps include a global phase 3 randomized study of quizartinib in FLT3-ITD(+) patients in 1st relapse planned to start in early 2014 pending final FDA feedback on our recommended starting dose.
Caught the falling knife a little early yesterday, but in for a solid position. Curious to see where we go from here. I like the number of candidates in the pipeline and the bullish sentiment across many analysts. All IMHO AMBI
Citi still bullish on Ambit despite no AA for quizartinib
03:03 PM ET · AMBI
Citi maintains a Buy rating on Ambit Biosciences (AMBI -35.2%).
Although Citi reportedly says AA for quizartinib wasn't baked into the share price.
Price target lowered to $17 from $19.
This should have only had a small pullback, volume was minimal, not sure of the share count but they are tight
No big deal, it's going back I, way way way oversold!!!!!!
down big on low vol* anyone know?
Followers
|
1
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
51
|
Created
|
10/11/13
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |